Skip to main content
MedNextMedNext
Drug ComparisonHMG-CoA reductase inhibitor

Atorvastatin vs Rosuvastatin

Clinical Comparison

Clinical Context

NICE recommends atorvastatin 20 mg for primary prevention and 80 mg for secondary prevention. Rosuvastatin is reserved for patients who do not achieve adequate LDL reduction on atorvastatin, or who cannot tolerate it due to drug interactions. Rosuvastatin is the most potent statin available, offering greater LDL reduction at equivalent doses.

Drug Profiles

Atorvastatin

HMG-CoA reductase inhibitor (statin)

Mechanism

Competitively inhibits HMG-CoA reductase in the liver, reducing cholesterol synthesis and upregulating LDL receptors

Indications

  • Primary prevention of cardiovascular disease
  • Secondary prevention post-MI/stroke
  • Familial hypercholesterolaemia
  • Type 2 diabetes with CVD risk factors

Common Doses

Primary prevention: 20 mg OD; Secondary prevention: 80 mg OD

Route

Oral

Onset & Duration

LDL reduction within 2 weeks; maximum effect 4-6 weeks; half-life 14 hours

Rosuvastatin

HMG-CoA reductase inhibitor (statin)

Mechanism

Competitively inhibits HMG-CoA reductase with highest binding affinity of all statins, reducing cholesterol synthesis

Indications

  • Hypercholesterolaemia (primary and familial)
  • Secondary prevention of cardiovascular events
  • When atorvastatin does not achieve LDL targets

Common Doses

5-10 mg OD initially; max 40 mg OD (20 mg max in Asian patients)

Route

Oral

Onset & Duration

LDL reduction within 1-2 weeks; maximum effect 4 weeks; half-life 19 hours

Key Differences

LDL-lowering potency

Atorvastatin

40-50% reduction at 20 mg; up to 55% at 80 mg

Rosuvastatin

45-55% at 10 mg; up to 63% at 40 mg — most potent statin

NICE position

Atorvastatin

First-line for primary and secondary prevention

Rosuvastatin

Reserved for atorvastatin failure or intolerance

Drug interactions

Atorvastatin

Metabolised by CYP3A4 — grapefruit, macrolides, azoles

Rosuvastatin

Minimal CYP metabolism — fewer interactions

Cost

Atorvastatin

Very cheap generic

Rosuvastatin

Slightly more expensive (still affordable)

Asian patients

Atorvastatin

No specific dose cap

Rosuvastatin

Max 20 mg in Asian patients (pharmacogenomic difference)

Renal excretion

Atorvastatin

Minimal renal excretion

Rosuvastatin

~28% renally excreted — caution in severe renal impairment

Key Advantages

Atorvastatin

  • NICE first-line statin for both primary and secondary prevention
  • Can be taken at any time of day (long half-life)
  • Extensive evidence base (CARDS, TNT, SPARCL trials)
  • Very cheap as generic

Rosuvastatin

  • Most potent statin — greatest LDL reduction per mg
  • Minimal CYP450 metabolism — fewer drug interactions
  • Can be taken at any time of day
  • Effective when atorvastatin fails to achieve targets

Key Cautions

Atorvastatin

  • Myalgia (5-10% of patients)
  • Rhabdomyolysis (rare)
  • Hepatotoxicity — check LFTs at baseline and 3 months
  • CYP3A4 interactions (clarithromycin, grapefruit, ciclosporin)
  • Avoid in pregnancy and breastfeeding

Rosuvastatin

  • Higher myopathy risk at 40 mg dose
  • Proteinuria at high doses
  • Dose cap at 20 mg for Asian patients (higher bioavailability)
  • Not first-line per NICE — used when atorvastatin is inadequate or not tolerated
  • Slightly higher cost than atorvastatin

Clinical Verdict

Start with atorvastatin per NICE guidelines. Switch to rosuvastatin if LDL targets are not met at maximum tolerated atorvastatin, or if CYP3A4 drug interactions are a concern.

Medical Disclaimer: This comparison is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making prescribing decisions. Verify all drug information with current clinical guidelines (BNF, NICE, SmPCs).

Full monographs for Atorvastatin & Rosuvastatin in the MedNext app

Complete dosing, interactions, contraindications, side effects, and more — covering 2,866 drugs with AI-powered search.

Download MedNext Formulary